

pertussis vaccines that induce antitoxin immunity and that are widely used in human populations argue against these predictions. The introduction of diphtheria toxoid vaccine at the beginning of the twentieth century led to a huge reduction in the number of people carrying the virulent form of this pathogen and to the persistence of non-virulent forms of the bacterium²⁻⁴.

Diphtheria is caused by a toxin that is synthesized by *Corynebacterium diphtheriae*, which allows this bacterium to obtain nutrients when resources in the immediate vicinity are scarce. To produce the toxin, *C. diphtheriae* must carry a viral *tox* gene (*tox*⁺ strain). Toxin production therefore confers a competitive advantage — cases of frank diphtheria are more contagious than cases of asymptomatic infection.

However, toxin production also carries a metabolic cost. As the toxin is neutralized in people who are immunized with diphtheria toxoid, its production is a drain on the bacterium, which is therefore at a competitive disadvantage. Accordingly, diphtheria has vanished from areas with long-standing and thorough diphtheria-toxoid vaccination programmes, whereas the *tox*⁻ *C. diphtheriae* strain has persisted, a change that is attributable to the selective pressure exerted by the vaccine⁵.

A similar mechanism could explain the impact of the pertussis-vaccination programme implemented in Sweden with a vaccine containing only pertussis toxoid, which also induces antitoxin immunity. This vaccine was introduced in 1995 in 11 Swedish counties to vaccinate all children between 6 months and 14 years of age. Four years later, the result of this programme was a large reduction in hospitalized pertussis cases, not only in vaccinated but also in non-vaccinated children (that is, infants younger than 6 months old and children older than 14 years). This demonstrates once again that antitoxin immunity does affect pathogen transmission⁶⁻⁸.

Gandon *et al.* also argue that vaccines that counteract pathogen propagation may be less effective, as reduced transmission will elicit increased virulence. As we do not yet have an example of this type of vaccine for humans, we do not know whether this will be the case. This may be important for HIV vaccines⁹ as well as for malaria, but we suspect that the reduction in transmission of a pathogen that replicates on mucosal surfaces will outweigh any possible increases in endogenous virulence.

Benoit Soubeyrand*, **Stanley A. Plotkin†**

*Department of Medical Affairs, Aventis Pasteur, 69007 Lyon, France

†Department of Paediatrics, University of Pennsylvania, Pennsylvania 19104, and Aventis Pasteur, Doylestown, Pennsylvania 18901, USA
e-mail: stanley.plotkin@aventis.com

1. Gandon, S., Mackinnon, M. J., Nee, S. & Read, A. F. *Nature* **414**, 751–755 (2001).
2. Pappenheimer, A. M. in *Bacterial Vaccines* (ed. Germanier, R.) 1–36 (Academic, Orlando, 1984).
3. Galazka, A. *J. Infect. Dis.* **181** (suppl.), 2–9 (2001).
4. Bergamini, M. *et al. Epidemiol. Infect.* **125**, 105–112 (2000).
5. Ewald, P. W. in *Concepts in Vaccine Development* (ed. Kaufmann, S. H. E.) 1–25 (de Gruyter, Berlin, 1996).
6. Taranger, J. *et al. Clin. Infect. Dis.* **33**, 1004–1009 (2001).
7. Schneerson, R., Robbins, J. B., Taranger, J., Lagergard, T. & Trollfors, B. *Lancet* **348**, 1289–1292 (1996).
8. Mortimer, A. E. & Wharton, M. in *Vaccines* (eds Plotkin, S. A. & Orenstein, W. A.) 140–157 (Saunders, Philadelphia, 1999).
9. Amara, R. R. *et al. Science* **292**, 69–74 (2001).

Gandon et al. reply — Soubeyrand and Plotkin question our contention that antitoxin vaccines may select for greater pathogen virulence, arguing that this has not been borne out in real-life cases of diphtheria and pertussis, in which the widespread use of antitoxin vaccines has led to a reduced incidence of severe disease. They explain this success in terms of direct effects by the toxin on transmission that are both beneficial and costly. They argue that antitoxin vaccines have relieved the pathogen of the cost of high virulence due to host mortality (as we do too), but that these vaccines also maintain the metabolic cost of producing the toxin, helping natural selection to weed out the toxin producers.

In our model, we assume no such effects of toxin production — we envisage toxin production as an unavoidable, unhelpful side-effect of parasite replication, as seems to be the case in malaria. The apparent contradiction between our predictions and the observations cited by Soubeyrand and Plotkin is therefore due to differences in the life histories of different pathogens.

Our model can easily be extended to incorporate the costs and benefits of toxin production by modifying the pathogen's fitness function as follows:

$$R_0[\tau] = \frac{\beta[\alpha + (1-r)\tau]}{(\delta + \alpha + (1-r)\tau)} e^{-c\tau}$$

where τ is the level of toxin production, r is the efficacy of the antitoxin vaccine, $e^{-c\tau}$ is the cost function of toxin production, β represents parasite transmission as an increasing function of both toxin production and another component of disease-induced mortality, α , and δ is natural host




Figure 1 Evolutionarily stable toxin production, τ^* , plotted against antitoxin vaccine efficacy, r , for different toxin-production costs, c . Here it is assumed that all hosts are vaccinated, but similar results emerge for intermediate levels of vaccination coverage. The following transmission function was used: $\beta[\alpha + (1-r)\tau] = b_1(\alpha + (1-r)\tau)^{b_2}$. Parameter values: $b_1 = 1$, $b_2 = 0.5$, $\delta = 1$, $\alpha = 0.2$.

mortality. Maximizing fitness yields the evolutionarily stable toxin production, τ^* , shown in Fig. 1. When the cost of toxin production is zero (as is assumed in our original model), virulence increases with vaccine efficacy. When the cost of toxin production is high, however, it counteracts the toxin's benefit to transmission, in which case optimal toxin production decreases with vaccine efficacy.

Figure 1 also shows that whereas highly effective antitoxin vaccines select for lower toxin production, imperfect vaccines can select for higher toxin production, which supports our argument that the use of imperfect vaccines can have negative consequences. The examples provided by Soubeyrand and Plotkin emphasize the need to understand how virulence and transmission relate to pathogen fitness for each disease of interest. Virulence evolution can occur in response to vaccination and other increases in host defence, both in positive ways, as Soubeyrand and Plotkin argue has occurred for diphtheria and pertussis, and in negative ways, as others have argued may be the case in Marek's disease¹ and myxomatosis².

Sylvain Gandon, Margaret J. Mackinnon, Sean Nee, Andrew F. Read

Institute of Cell, Animal and Population Biology, University of Edinburgh, Edinburgh EH9 3JT, UK
e-mail: sylvain.gandon@ed.ac.uk

1. Witter, R. L. *Acta Vet. Hung.* **45**, 251–266 (1997).
2. Fenner, F. & Fantini, B. *Biological Control of Vertebrate Pests: The History of Myxomatosis — an Experiment in Evolution* (CABI, Wallingford, UK, 1999).

brief communications is intended to provide a forum for both brief, topical reports of general scientific interest and technical discussion of recently published material of particular interest to non-specialist readers. Priority will be given to contributions that have fewer than 500 words, 10 references and only one figure. Detailed guidelines are available on *Nature's* website (www.nature.com/nature) or on request from nature@nature.com